Levosimendan, a new inotropic and vasodilator agent

Anesthesiology

Volumn 104, Issue 3, 2006, Pages 556-569

  Toller, Wolfgang G ^a   Stranz, Christian ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ADENOSINE TRIPHOSPHATE; ANTICOAGULANT AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; CARVEDILOL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DRUG METABOLITE; ENALAPRIL; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; NITRIC ACID DERIVATIVE; OR 1855; PHOSPHODIESTERASE III INHIBITOR; PIMOBENDAN; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; VASODILATOR AGENT; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CALCIUM; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANEMIA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARRHYTHMOGENESIS; CALCIUM CELL LEVEL; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONFERENCE PAPER; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; EXCITATION CONTRACTION COUPLING; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART RHYTHM; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOXEMIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HEART CONTRACTION; HEART INFARCTION; HEART RATE; METABOLISM; REVIEW;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CALCIUM; CARDIOTONIC AGENTS; HEART RATE; HUMANS; HYDRAZONES; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE INHIBITORS; POTASSIUM CHANNELS; PYRIDAZINES; VASODILATOR AGENTS;

EID: 33645498542     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200603000-00024     Document Type: Conference Paper

References (129)

1. Thackray S, Easthaugh J, Freemantle N, Cleland JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: A meta-regression analysis. Eur Heart J 2002; 4:515-29
2. Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-33
3. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138:78-86
4. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325:1468-75
5. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 2002; 287:1541-7
6. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM: Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41:997-1003
7. Hasenfuss G, Holubarsch C, Heiss HW, Meinertz T, Bonzel T, Wais U, Lehmann M, Just H: Myocardial energetics in patients with dilated cardiomyopathy: Influence of nitroprusside and enoximone. Circulation 1989; 80:51-64
8. Scoote M, Williams AJ: Myocardial calcium signalling and arrhythmia pathogenesis. Biochem Biophys Res Commun 2004; 322:1286-309
9. 2+ sensitizers. Cardiovasc Drugs Ther 2001; 15:397-403
10. Endoh M: Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 2002; 40:323-38
11. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX: The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43:2177-82
12. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77:107-13
13. Lilleberg J, Ylonen V, Lehtonen L, Toivonen L: The calcium sensitizer levosimendan and cardiac arrhythmias: An analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38:80-4
14. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360:196-202
15. Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22:1527-60
16. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Moreno R, Singer M, Singh S, Tendera M, Thygesen K: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384-416
17. Fabiato A: Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 1983; 245:C1-14
18. Than N, Shah N, White J, Lee JA, Orchard CH: Effects of acidosis and hypoxia on the response of isolated ferret cardiac muscle to inotropic agents. Cardiovasc Res 1994; 28:1209-17
19. 2+ sensitivity by moderate hypothermia in guinea pig isolated hearts. Am J Physiol Heart Circ Physiol 1999; 277:H2321-32
20. (2+) sensitivity during hypothermia in isolated guinea pig beating hearts. Anesth Analg 2001; 93:846-52
21. Hajjar RJ, Schwinger RH, Schmidt U, Kim CS, Lebeche D, Doye AA, Gwathmey JK: Myofilament calcium regulation in human myocardium. Circulation 2000; 101:1679-85
22. 2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med 2001; 163:362-7
23. 2+], and NADH with dysfunction after global ischemia in intact hearts. Am J Physiol Heart Circ Physiol 2001; 280:H280-93
24. Perez NG, Marban E, Cingolani HE: Preservation of myofilament calcium responsive ness underlies protection against myocardial stunning by ischemic preconditioning. Cardiovasc Res 1999; 42:636-43
25. 2+ mediated through alpha- and beta-adrenoceptors. Circ Res 1988; 62:247-65
26. Strang K, Sweitzer N, Greaser M, Moss R: Beta-adrenergic receptor stimulation increases unloaded shortening velocity of skinned single ventricular myocytes from rats. Circ Res 1994; 74:542-9
27. 2+ in cardiac myocytes. Circ Res 1992; 71:870-82
28. Solaro RJ: Modulation of cardiac myofilament activity by protein phosphorylation, Handbook of Physiology: Section 2, The Cardiovascular System. Volume 1, The Heart. Edited by Page E, Fozzard HA, Solaro RJ. New York, Oxford University Press, 2001, pp 264-300
29. McConnell BK, Moravec CS, Morano I, Bond M: Troponin I phosphorylation in spontaneously hypertensive rat heart: Effect of beta-adrenergic stimulation. Am J Physiol 1997; 273:H1440-51
30. Kogler H, Ruegg JC: Cardiac contractility: Modulation of myofibrillar calcium sensitivity by beta-adrenergic stimulation. Isr J Med Sci 1997; 33:1-7
31. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA: ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2004; 110:e340-437
32. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB: Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27:1859-66
33. 2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994; 269:28584-90
34. 2+-sensitization. Eur J Pharmacol 2004; 486:1-8
35. Hajjar RJ, Schmidt U, Helm P, Gwathmey JK: Ca++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 1997; 280:247-54
36. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB: Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995; 25:794-801
37. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998; 30:1115-28
38. McGough MF, Pagel PS, Lowe D, Hettrick DA, Kersten JR, Warltier DC: Effects of levosimendan on left ventricular function: Correlation with plasma concentrations in conscious dogs. J Cardiothorac Vasc Anesth 1997; 11:49-53
39. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenpera M: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19:660-8
40. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z: The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486:67-74
41. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98:2141-7
42. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, Vahlensieck U, Zimmermann N: Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997; 280:277-83
43. 2+]; in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 1997; 339:97-100
44. Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO: Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 2003; 55:544-51
45. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1903-12
46. 2+-activation and inotropic effect of pimobendan: Comparison with milrinone. Circ Res 1988; 63:911-22
47. Haikala H, Kaheinen P, Levijoki J, Linden IB: The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997; 34:536-46
48. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ: Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40:465-71
49. Takahashi R, Talukder MA, Endoh M: Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 2000; 400:103-12
50. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107:81-6
51. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23:1422-32
52. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, Foster E, Chatterjee K: Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111:1504-9
53. Kaheinen P, Pollesello P, Levijoki J, Haikala H: Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001; 37:367-74
54. Gruhn N, Nielsen Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J: Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31:741-9
55. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, Kaye AD: An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 2002; 94:1427-33
56. Pagel PS, Hettrick DA, Warltier DC: Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996; 119:609-15
57. Pagel PS, Hettrick DA, Warltier DC: Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 1996; 91:296-307
58. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102:2222-7
59. Holm J, Pataricza J, Petri A, Toth GK, Balogh A, Varro A, Papp JG: Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol 2004; 94:271-3
60. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG: Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000; 52:213-7
61. ATP channels. Anesth Analg 2000; 90:5-11
62. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG: Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17:115-21
63. Yokoshiki H, Sperelakis N: Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 2003; 17:111-3
64. Bowman P, Haikala H, Paul RJ: Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999; 288:316-25
65. Haikala H, Linden IB: Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995; 26 (suppl 1):S10-9
66. Lilleberg J, Sundberg S, Hayha M, Akkila J, Nieminen MS: Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994; 47:267-74
67. Harkin CP, Pagel PS, Tessmer JP, Warltier DC: Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995; 26:179-88
68. Ploechl W, Rajek A: The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004; 32:471-5
69. Lilleberg J, Sundberg S, Nieminen MS: Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26 (suppl 1):S63-9
70. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, Lehtonen L: Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: A dosing interval study. J Clin Pharmacol 2004; 44:1143-50
71. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ: Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002; 42:43-51
72. Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, Nikfardjam M, Berger R, Heinz G: Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47:1251-6
73. Nanas JN, Papazoglou PP, Terrovitis JV, Kanakakis J, Dalianis A, Tsolakis E, Tsagalou EP, Agrios N, Christodoulo K, Anastasiou-Nana MI: Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol 2004; 94:1329-32
74. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH: Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: A case series. Med Sci Monit 2004; 10:MT89-93
75. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC: Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34:219-28
76. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, Warltier DC: Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997; 29:563-73
77. Kyrzopoulos S, Adamopoulos S, Parissis JT, Rassias J, Kostakis G, Iliodromitis E, Degiannis D, Kremastinos DT: Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 2005; 99:409-13
78. Janssen PM, Datz N, Zeitz O, Hasenfuss G: Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000; 404:191-9
79. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, Cheng CP: Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005; 288:H914-22
80. Leather HA, Ver Eycken K, Segers P, Herijgers P, Vandermeersch E, Wouters PF: Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med 2003; 31:2339-43
81. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio Pulkki LM: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68:522-31
82. Schwarte LA, Picker O, Bornstein SR, Fournell A, Scheeren TW: Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med 2005; 33:135-42
83. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietropaoli P: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31:638-44
84. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M: Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29:2185-93
85. Du Toit EF, Muller CA, McCarthy J, Opie LH: Levosimendan: Effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290:505-14
86. Lynch JJ Jr, Uprichard AC, Frye JW, Driscoll EM, Kitzen JM, Lucchesi BR: Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. J Cardiovasc Pharmacol 1989; 14:585-97
87. ATP channel opener. Eur J Pharmacol 2001; 428:311-4
88. Kopustinskiene DM, Pollesello P, Saris NE: Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004; 68:807-12
89. + channel in rat arterial myocytes. Eur J Pharmacol 1997; 333:249-59
90. + channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283:375-83
91. Gross GJ, Fryer RM: Mitochondrial K(ATP) channels: Triggers or distal effectors of ischemic or pharmacological preconditioning? Circ Res 2000; 87:431-3
92. Gross GJ, Peart JN: KATP channels and myocardial preconditioning: An update. Am J Physiol Heart Circ Physiol 2003; 285:H921-30
93. Rump AF, Acar D, Rosen R, Klaus W: Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994; 74:244-8
94. + channels and myocardial preconditioning. Circ Res 1999; 84:973-9
95. Fischbach PS, White A, Barrett TD, Lucchesi BR: Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther 2004; 309:554-9
96. Wilde AA, Janse MJ: Electrophysiological effects of ATP sensitive potassium channel modulation: Implications for arrhythmogenesis. Cardiovasc Res 1994; 28:16-24
97. Singh BN, Lilleberg J, Sandell E-P, Ylonen V, Lehtonen L, Toivonen L: Effects of levosimendan on cardiac arrhythmia: Electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999; 83:16-20
98. Rump AF, Acar D, Klaus W: A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 1994; 112:757-62
99. 2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts. Cardiovasc Res 2003; 59:912-25
100. Eriksson O, Pollesello P, Haikala H: Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. J Cardiovasc Pharmacol 2004; 44:316-21
101. Du Toit E, Hofmann D, McCarthy J, Pineda C: Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001; 86:81-7
102. Tassani P, Schad H, Heimisch W, Bernhard Abt A, Ettner U, Mendler N, Lange R: Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther 2002; 16:435-41
103. Pieske B: Levosimendan in regional myocardial ischemia. Cardiovasc Drugs Ther 2002; 16:379-81
104. Kristof E, Szigeti G, Papp Z, Bodi A, Ball NA, Walsh RA, Edes I: The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts. Basic Res Cardiol 1999; 94:223-30
105. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC: Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997; 85:23-9
106. Pagel PS, Haikala H, Pentikainen PJ, Toivonen ML, Nieminen MS, Lehtonen L, Papp JG, Warltier DC: Phannacology of levosimendan: A new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996; 14:286-316
107. Shammas FV, Dickstein K: Clinical pharmacokinetics in heart failure. Clin Pharmacokinet 1988; 15:94-113
108. Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikainen PJ: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26 (suppl 1):S57-62
109. Kristof E, Szigeti G, Papp Z, Bodi A, Facsko A, Kovacs L, Papp JG, Kranias EG, Edes I: Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts: Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function. Ann N Y Acad Sci 1998; 853:316-9
110. Antila S, Kivikko M, Lehtonen L, Elia J, Heikkila A, Pohjanjousi P, Pentikainen PJ: Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004; 57:412-5
111. Lehtonen L, Sundberg S: The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 2002; 58:449-52
112. Antila S, Eha J, Heinpalu M, Lehtonen L, Loogna I, Mesikepp A, Planken U, Sandell EP: Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996; 49:451-8
113. Sundberg S, Lehtonen L: Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 2000; 55:793-9
114. Poder P, Eha J, Antila S, Heinpalu M, Planken U, Loogna I, Mesikepp A, Akkila J, Lehtonen L: Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 2003; 17:451-8
115. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L: Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000; 35:664-9
116. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L: Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995; 75:1061-6
117. Labriola C, Siro Brigiani M, Carrata F, Santangelo E, Amantea B: Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42:204-11
118. Barisin S, Husedzinovic I, Sonicki Z, Bradic N, Barisin A, Tonkovic D: Levosimendan in off-pump coronary artery bypass: A four-times masked controlled study. J Cardiovasc Pharmacol 2004; 44:703-8
119. Mebazaa A, Karpati P, Renaud E, Algotsson L: Acute right ventricular failure: From pathophysiology to new treatments. Intensive Care Med 2004; 30:185-96
120. Noto A, Giacomini M, Palandi A, Stabile L, Reali Forster C, Iapichino G: Levosimendan in septic cardiac failure. Intensive Care Med 2005; 31:164-5
121. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A: Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg 2004; 98:822-4
122. McGough MF, Pagel PS, Lowe D, Hettrick DA, Warltier DC: Levosimendan potentiates the inotropic actions of dopamine in conscious dogs. J Cardiovasc Pharmacol 1996; 28:36-47
123. Toller W, Woelkart G, Stranz C, Brunner F: Contractile action of levosimendan and epinephrine during acidosis. Eur J Pharmacol 2005; 507:199-209
124. Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV, Kanakakis J, Nanas SN, Alexopoulos GP, Anastasiou-Nana MI: Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005; 95:768-71
125. Braun JP, Schneider M, Kastrup M, Liu J: Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg 2004; 26:228-30
126. Behrends M, Peters J: The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 2003; 29:1802-7
127. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E: Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5:457-62
128. Cleland JGF, Takala A, Apajasalo M, Zethraeus N, Kobelt G: Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: An analysis based on the international LIDO trial. Eur J Heart Fail 2003; 5:101-8
129. Swedberg K, Kjekshus J, Snapinn S: Long term survival in severe heart failure patients treated with enalapril: Ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20:136-9